New York, June 4, 2026, 19:00 EDT
- BioLife Solutions traded at $27.09, down 17 cents, or 0.6%. The SPDR S&P Biotech ETF gained around 2.7%.
- BioLife put out a new investor presentation on June 3, according to an SEC filing. The company said it would use the presentation at the Jefferies Global Healthcare Conference and in other investor meetings.
- A June 4 filing showed Casdin Capital and related entities held 4.76 million shares, for a 9.7% stake in the company.
BioLife Solutions shares dropped late Thursday in U.S. trading, underperforming other biotech names, after the cell-therapy tools company published a new investor deck and Casdin Capital revealed a big stake. The Nasdaq stock traded at $27.09, off 17 cents, or 0.6%. The SPDR S&P Biotech ETF was up around 2.7%.
BioLife Solutions is aiming to steer investors toward a 2026 growth story, after shifting its portfolio to cell processing products. The company, based in Bothell, Washington, filed a June 3 Form 8-K, telling investors the latest presentation could be used at the Jefferies Global Healthcare Conference or in meetings with investors and analysts.
The deck kept its 2026 revenue growth target at 17% to 20%. Management is projecting positive net income under U.S. GAAP and more growth in adjusted EBITDA margin. Adjusted EBITDA takes out interest, taxes, depreciation, amortization, and some other line items. It is used to track operating results.
BioLife makes preservation media and cell-processing tools for cell and gene therapy. The company said its products are listed in over 950 active cell-based therapy trials around the world and used in about 90% of FDA-approved cell therapies that matter commercially, according to its own presentation.
Casdin Capital, Casdin Partners Master Fund and Eli Casdin reported shared voting and dispositive power over 4,757,165 BioLife shares, or 9.7% of the class, according to a separate Schedule 13G beneficial-ownership filing. The filing said the shares were not picked up or held to change or influence control of the company.
BioLife’s first-quarter revenue rose 25% from a year ago to $27.5 million, according to its latest available numbers. The company posted GAAP net income of $1.2 million. Cash, cash equivalents and marketable securities totaled $111.5 million at the end of March. CEO Roderick de Greef said it was “a solid start to 2026,” pointing to “healthy demand for our biopreservation media.” He said BioLife was still “confident in our full year outlook.” PR Newswire
BioLife is up against some big life-sciences tool makers. Thermo Fisher Scientific, Danaher’s Cytiva, and Sartorius all show up in industry reports tracking cell and gene therapy tools and reagents. The bigger names give BioLife a narrower, more focused profile in the field, but the company lacks their size.
But the setup isn’t all upside. BioLife’s annual report flagged that a lot of rivals have more money, bigger manufacturing, and stronger marketing. The company also pointed out that three customers made up 29% of 2025 revenue, and CryoStor products accounted for 82%. Delays in therapy launches, clinical funding, or customer orders could hit results fast.
BioLife’s new filing didn’t add any fresh earnings numbers. The update again raised the same issue for the market: can BioLife keep growing from its place in CGT manufacturing, and do it without eating into margins or making one product line carry all the weight?
